Clinical significance of cellular drug resistance in childhood leukemia.

Clinical significance of cellular drug resistance in childhood leukemia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Clinical significance of cellular drug resistance in childhood leukemia. Abstract Text:

G J L Kaspers,A J P Veerman,

Cellular drug resistance is an important determinant of the response to chemotherapy, and its precise measurement may have clinical relevance. Potential applications are: prognostic factor for risk-group stratification, tailored chemotherapy for subgroups or individual patients with a specific cellular drug resistance profile, determination of cross-resistance patterns, study of drug interactions, study of resistance modulation or circumvention, selection of patients for phase II studies and screening for the cytotoxicity of novel compounds. The colorimetric 4-day MTT assay is a frequently used method. However, a distinction between malignant and non-malignant cells cannot be made, which should be taken into account. In the case of a relatively high percentage of contaminating non-malignant cells, the differential staining cytotoxicity (DiSC) assay can be used. The MTT assay's technical success percentage is about 80% for fresh ALL and AML samples. For methotrexate (MTX) a different assay must be used, such as the thymidylate synthase inhibition assay (TSIA). The MTT assay measures the number of living cells that survived drug exposure. Therefore, the effect of many if not most drugs to induce leukemia cell death by apoptosis is also included. This review mainly summarizes the data on cellular drug resistance in childhood leukemia, as obtained by the MTT assay and TSIA, in our laboratory in Amsterdam. These data clearly demonstrate the significant relation between in vitro cellular drug resistance and clinical and cell biological features and short- and long-term clinical outcome in childhood leukemia. In conclusion, cellular drug resistance testing provides clinically relevant information that can be available within 1 week and can be performed successfully in the vast majority of leukemia samples. The data are more and more being used and being considered for use in clinical trials in leukemia.

Clinical significance of cellular drug resistance in childhood leukemia. Publishing Authors By Initials

GJ Kaspers,AJ Veerman,

For similar diagnosis: prognosis research abstracts see: diagnosis: prognosis research

PUBMED ID PMID:

MEDLINE DATE:

Clinical significance of cellular drug resistance in childhood leukemia. Journal Published:

PUBLICATION TYPE: Review

Journal: Recent results in cancer research. Fortschritte de

VOLUME: 161

Page Numbers: 196-220

Journal Abbreviation: Recent Results Cancer Res.

ISSN: 0080-0015

DAY: 13

MONTH: 02

YEAR: 2003

Clinical significance of cellular drug resistance in childhood leukemia. Information

Number of References: 70

LANGUAGE: eng

NlmUniqueID: 44671

Clinical significance of cellular drug resistance in childhood leukemia. Keywords Mesh Terms:

KEYWORDS: Prognosis

MESH TERMS: drug therapy

Chemical & Substance for Abstract: Clinical significance of cellular drug resistance in childhood leukemia. Information

Substance Name: Antineoplastic Agents

Registry Number: 0

Grant and Affiliation Information for Clinical significance of cellular drug resistance in childhood leukemia.

AFFILIATION: Department of Pediatric Hematology/Oncology, VU University Medical Center, De Boelelaan 1117, 1081 Amsterdam, The Netherlands. gjl.kaspers@vumc.nl

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Recent Results Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Clinical significance of cellular drug resistance in childhood leukemia Related Publications

• Adsorption to hydroxyapatite of partially deglycosylated human salivary mucins in competition with phosvitin and phytate.
• Attitude of health-care providers toward childhood leukemia patients with different socio-economic status.
• Cellular drug sensitivity of immunophenotypic subgroups of childhood acute lymphoblastic leukemia.
• Circumvention of glucocorticoid resistance in childhood leukemia.
• Clinical significance of cellular drug resistance in childhood leukemia.
• Health-care providers' compliance with childhood acute lymphoblastic leukemia protocol in Indonesia.
• [Growth hormone therapy and leukemia]
• [Pearson's syndrome: a multi-system disorder based on a mt-DNA deletion]
• [Problems of differential diagnosis in children with acute leukemia]
• [Sedation and analgesia in interventions]
• [The treatment of recurrence in children with acute lymphatic leukemia. Current results and various developments]
• [Thrombocytopenia and absent radii syndrome (TAR). Case report and literature discussion]